Decrease of neurofilament is associated with reduction of clinical disease activity in glatiramer acetate treated people with multiple sclerosis

被引：0
|
作者：
Konofalska, U. [1 ]
Akgun, K. [1 ]
Proschmann, U. [1 ]
Haase, R. [2 ]
Ziemssen, T. [1 ]
机构：
[1] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany
[2] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P599
引用
收藏
页码：526 / 527
页数：2
相关论文
共 50 条
  • [31] Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
    Foong, Yi Chao
    Zhu, Chao
    Merlo, Daniel
    Gresle, Melissa
    Buzzard, Katherine
    Zhong, Michael
    Yeh, Wei
    Jokubaitis, Vilija
    Skibina, Olga
    Ozakbas, Serkan
    Patti, Francesco
    Grammond, Pierre
    Amato, Maria Pia
    Kalincik, Tomas
    Horakova, Dana
    Havrdova, Eva
    Weinstock-Guttman, Bianca
    Lechner-Scott, Jeannette
    Boz, Cavit
    Sa, Maria Jose
    Butzkueven, Helmut
    van der Walt, Anneke
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 32 - 33
  • [32] Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
    Zarzuelo-Romero, Maria Jose
    Perez-Ramirez, Cristina
    Cura, Yasmin
    Carrasco-Campos, Maria Isabel
    Marangoni-Iglecias, Luciana Maria
    Ramirez-Tortosa, Maria Carmen
    Jimenez-Morales, Alberto
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (10):
  • [33] Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial
    Cheshmavar, Masoumeh
    Mirmosayyeb, Omid
    Badihian, Negin
    Badihian, Shervin
    Shaygannejad, Vahid
    ACTA NEUROLOGICA SCANDINAVICA, 2021, 143 (02): : 178 - 187
  • [34] Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
    Valenzuela, R. M.
    Kaufman, M.
    Balashov, K. E.
    Ito, K.
    Buyske, S.
    Dhib-Jalbut, S.
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 300 : 59 - 65
  • [35] Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
    Foong, Yi Chao
    Merlo, Daniel
    Gresle, Melissa
    Buzzard, Katherine
    Zhong, Michael
    Yeh, Wei Zhen
    Jokubaitis, Vilija
    Monif, Mastura
    Skibina, Olga
    Ozakbas, Serkan
    Patti, Francesco
    Grammond, Pierre
    Amato, Maria Pia
    Kalincik, Tomas
    Horakova, Dana
    Kubala Havrdova, Eva
    Weinstock-Guttman, Bianca
    Lechner Scott, Jeanette
    Boz, Cavit
    Sa, Maria Jose
    Butzkueven, Helmut
    van der Walt, Anneke
    Zhu, Chao
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (08): : 767 - 774
  • [36] A longitudinal observational study of a cohort of patients with relapsingremitting multiple sclerosis treated with glatiramer acetate
    Debouverie, M.
    Moreau, T.
    Lebrun, C.
    Heinzlef, O.
    Brudon, F.
    Msihid, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (11) : 1266 - 1274
  • [37] Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate
    Chiarini, M.
    Sottini, A.
    Ghidini, C.
    Zanotti, C.
    Serana, F.
    Rottoli, M.
    Zaffaroni, M.
    Bergamaschi, R.
    Cordioli, C.
    Capra, R.
    Imberti, L.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (02) : 218 - 227
  • [38] Neuroprotective Effect of Glatiramer Acetate on Neurofilament Light Chain Leakage and Glutamate Excess in an Animal Model of Multiple Sclerosis
    Aharoni, Rina
    Eilam, Raya
    Lerner, Shaul
    Shavit-Stein, Efrat
    Dori, Amir
    Chapman, Joab
    Arnon, Ruth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [39] T Cell Activation and Th2-related Gene Expression Correlate with Disease Activity in Glatiramer Acetate-treated Multiple Sclerosis
    Sellebjerg, Finn
    Krakauer, Martin
    Hesse, Don
    Lund, Henrik
    Limborg, Signe
    Sondergaard, Helle
    Sorensen, Per
    CLINICAL IMMUNOLOGY, 2009, 131 : S70 - S70
  • [40] Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients
    Szilasiova, Jarmila
    Rosenberger, Jaroslav
    Fedicova, Miriam
    Mikula, Pavol
    Urban, Peter
    Gdovinova, Zuzana
    Vitkova, Marianna
    Hanes, Jozef
    Stevens, Eva
    EUROPEAN NEUROLOGY, 2021, 84 (04) : 272 - 279
12345